| Literature DB >> 28429073 |
Karina Barreiro1, Harry Holthofer2,3.
Abstract
Proteomic and genomic techniques have reached full maturity and are providing unforeseen details for the comprehensive understanding of disease pathologies at a fraction of previous costs. However, for kidney diseases, many gaps in such information remain to inhibit major advances in the prevention, treatment and diagnostics of these devastating diseases, which have enormous global impact. The discovery of ubiquitous extracellular vesicles (EV) in all bodily fluids is rapidly increasing the fundamental knowledge of disease mechanisms and the ways in which cells communicate with distant locations in processes of cancer spread, immunological regulation, barrier functions and general modulation of cellular activity. In this review, we describe some of the most prominent research streams and findings utilizing urinary extracellular vesicles as highly versatile and dynamic tools with their extraordinary protein and small regulatory RNA species. While being a highly promising approach, the relatively young field of EV research suffers from a lack of adherence to strict standardization and carefully scrutinized methods for obtaining fully reproducible results. With the appropriate guidelines and standardization achieved, urine is foreseen as forming a unique, robust and easy route for determining accurate and personalized disease signatures and as providing highly useful early biomarkers of the disease pathology of the kidney and beyond.Entities:
Keywords: Biomarkers; Extracellular vesicles; Kidney disease; MicroRNA; Urine
Mesh:
Substances:
Year: 2017 PMID: 28429073 PMCID: PMC5487850 DOI: 10.1007/s00441-017-2621-0
Source DB: PubMed Journal: Cell Tissue Res ISSN: 0302-766X Impact factor: 5.249
Fig. 1Biogenesis of microRNA (miRNA), extracellular vesicles (EV) and uptake mechanisms. miRNAs are transcribed by RNA polymerase II from chromosomal DNA into primary RNA (Pri-miRNA; 1-3 kb). Pri-miRNA is processed by Drosha into precursor miRNA (Pre-miRNA). Pre-miRNA is transported to the cytoplasm and cleeved into miRNA/miRNA duplices (∼22 bp) by Dicer. miRNA duplex strands separate with the incorporation of the protein Argonaute (AGO) and RNA-induced silencing complex (Risk; Xu et al. 2013; Sohel 2016; Tomasetti et al. 2017). miRNA can be packed in the EV or be exported as protein-miRNA complexes (Arroyo et al. 2011; Canfran-Duque et al. 2014). Exosomes are derived from the endocytic pathway and their biogenesis requires multiprotein complexes called Endosomal Sorting Complex Required for Transport. Microvesicles are formed by the outward budding of the plasma membrane, whereas apoptotic bodies are vesicles released from cells that undergo apoptosis (Akers et al. 2013; Morrison et al. 2016). EV are taken up by recipient cells by a variety of mechanisms including endocytosis (mediated by lipid rafts, clathrin or caveolin), pinocytosis, phagocytosis and membrane fusion (Mulcahy et al. 2014). Proteins present on the EV can trigger signaling pathways in the target cells or be involved in antigen presentation (Thery et al. 2009; El Andaloussi et al. 2013). miRNA-protein complexes are also internalized by interaction with specific receptors on the recipient cell. High-density lipoprotein (HDL) associated with miRNA (miRNA-HDL) interacts with scavenger receptor class B type 1 (SR-B1; Canfran-Duque et al. 2014). miRNA-AGO-2 interacts with neuropilin-1 (NRP1; Prud’homme et al. 2016). EE Early endosome, MVB multivesicular body, NPM1 nucleophosmin 1, OMVs outer membrane vesicles, dsRNA double-stranded RNA
Classification and characteristics (Thery et al. 2009; van der Pol et al. 2012; Akers et al. 2013; Ciardiello et al. 2016) of extracellular vesicles (EM electron microscopy, ND not determined, TNFRI tumour necrosis factor receptor I)
| Characteristic | Exosomes | Microvesicles | Ectosomes | Membrane particles | Exosome-like vesicles | Apoptotic bodies |
|---|---|---|---|---|---|---|
| Size | 50-100 nm | 20-1000 nm | 50-200 nm | 50–80 to 600 nm | 20-50 nm | 50-500 nm and 500-4000 nm |
| Density in sucrose | 1.13–1.19 g/ml | ND | ND | 1.04–1.07 g/ml | 1.1 g/ml | 1.16–1.28 g/ml |
| EM morphology | Cup shape | Irregular shape and electron-dense | Bilamellar round structures | Round | Irregular shape | Heterogeneous |
| Sedimentation | 100,000 g | 10,000–20,000 g | 160,000–200,000 g | 100,000–200,000 g | 175,000 g | 1200 g, 10,000 g or 100,000 g |
| Lipid composition | Enriched in cholesterol, sphingomyelin and ceramide; contain lipid rafts; expose phosphatidylserine | Expose phosphatidylserine | Enriched in cholesterol and diacylglycerol; expose phosphatidylserine | ND | Do not contain lipid rafts | Expose phosphatidylserine |
| Main protein markers | Tetraspanins (CD63, CD9), Alix and TSg101 | Integrins, selectins and CD40 ligand, VCAMP3, ARF6 | CR1 and proteolytic enzymes; no CD63 | CD133; no CD63 | TNFRI | Histones, caspase3, C3b |
| Intracellular origin | Internal compartments (endosomes) | Plasma membrane | Plasma membrane | Plasma membrane | Internal compartments | Plasma membrane, endoplasmic reticulum |
Characteristics of bacterial extracellular vesicles (ND not determined, EM electron microscopy)
| Characteristics | Bacterial extracellular vesicles | |
|---|---|---|
| Gram-negative | Gram-positive | |
| Size | 20-300 nm | 20-100 nm |
| Density in sucrose | 1.20–1.22 g/ml | ND |
| EM morphology | Round | Round |
| Sedimentation | 150,000 | 150,000 |
| Lipid compositiona | Phosphatidylglycerol, phosphatidylethanolamine ( | Palmitic acid, myristic acid ( |
| Main protein markers | Outer membrane proteins, virulence factors | Bacterial adhesion and invasion proteins, host cell modulation proteins |
| Intracellular origin | Bacterial outer membrane | Cell membrane |
| References | Lee et al. | Gurung et al. |
aVariability between strains, species
Advantages and disadvantages of isolation methods for urinary extracellular vesicles (DC differential centrifugation, CHAPS 3-((3-cholamidopropyl) dimethylammonio)-1-propanesulfonate, DTT dithiothreitol, SEC size exclusion chromatography, THP Tamm-Horsfall glycoprotein, uEV urinary extracellular vesicles)
| Method | Advantages | Disadvantages | |
|---|---|---|---|
| DC | Vesicle enrichment as a pellet | No standard conditions for: | Not applicable for large volume of samples, not suitable for samples from large cohort of patients. Relatively expensive because of devise setup/reagent price |
| DC + CHAPS treatment | Protein activity prevention | ||
| DC + DTT treatment | Removal of, for example, THP excess in sample | Not suitable for protein activity assessment designated samples | |
| DC + SEC | |||
| Nano-membrane filtration | Removal of cell debris and urinary casts | Differences in removal of larger (>0.22 μm or more) vesicles without assessment of their importance for biomarkers screening; major loss of uEVs on the filter | |
| DC + microfiltration | |||
| DC + nanofiltration | |||
| DC + ultrafiltration | |||
| DC + sucrose gradient | Vesicle separation according to density | Highly time consuming | |
| Ultrafiltration + DC | |||
| Exoquick | No need for ultracentrifugation step | Overtly expensive when applied to large volumes | |
| Total exosome isolation reagent | |||
| Hydrostatic filtration dialysis (HFD) | Inexpensive, quick, versatile. Applicable to large sample volumes and large sample numbers; no need for special machinery or highly trained personnel | ||